Head-to-head evidence
Divozilimab vs Ublituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Divozilimab
Developed by Biocad
NCT06987851 · Phase 3 · completed
This was an open-label, single-group extension study without a comparator, enrolling 44 participants who continued from the prior BCD-132-4/MIRANTIBUS study after earlier BCD-132 treatment. Its primary endpoint was the clinical measure of annualized relapse rate at 48 and 96 weeks, but the result was not reported.
Ublituximab
Marketed by TG THERAPEUTICS, INC.
NCT03277261 · Phase 3 · completed
This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).
Next expected readout: October 2026 · NCT07211633 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ublituximab's landscape